IASLC North America

Articles

The agent has a high affinity and specificity for interleukin-1 beta.

Phase III CANOPY Studies to Investigate Canakinumab in NSCLC

The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.

Pembrolizumab Shows Benefit for NSCLC Patients with Brain Metastases

NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.

Neutrophil-to-Lymphocyte Ratio Helps Predict Survival in Stage III NSCLC

Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.

Sequential TKI Treatment Improves OS in EGFR T790M-Positive NSCLC

Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.

IASLC North America | Conference